Comparison of the action of NSC 680410 and STI571 in chronic myelogenous leukemia cells in vitro.

被引：0
|
作者：
Mow, BM
Hallgren, CG
Svingen, PA
Tefferi, A
Sausville, EA
Kaufmann, SH
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Div Oncol Res, Rochester, MN USA
[3] NCI, Dev Therapeut Program, Bethesda, MD 20892 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1493
引用
收藏
页码：346A / 346A
页数：1
相关论文
共 50 条
  • [31] The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro
    Korycka, A
    Robak, T
    LEUKEMIA & LYMPHOMA, 2003, 44 (09) : 1549 - 1555
  • [32] Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines
    Ioannis A. Avramis
    Walter E. Laug
    Edward A. Sausville
    Vassilios I. Avramis
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 307 - 318
  • [33] The type of the bcr-abl transcript predicts the cytogenetic responses in chronic myelogenous leukemia patients treated with Glivec(STI571).
    Plouzeau, C
    Petinay, P
    Guilhot, J
    Brizard, F
    Bourmeyster, N
    Kitzis, A
    Brizard, A
    Bertaud, P
    Guilhot, F
    BLOOD, 2001, 98 (11) : 266B - 266B
  • [34] In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells
    Scappini, B
    Onida, F
    Kantarjian, HM
    Dong, L
    Verstovsek, S
    Keating, MJ
    Beran, M
    CANCER, 2002, 94 (10) : 2653 - 2662
  • [35] Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia
    Brouard, MC
    Prins, C
    Mach-Pascual, S
    Saurat, JH
    DERMATOLOGY, 2001, 203 (01) : 57 - 59
  • [36] Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
    Holtz, MS
    Slovak, ML
    Zhang, FY
    Sawyers, CL
    Forman, SJ
    Bhatia, R
    BLOOD, 2002, 99 (10) : 3792 - 3800
  • [37] Gleevec (STI571) selectively inhibits growth of chronic myelogenous leukemia primitive progenitors through reversal of abnormally increased proliferation.
    Holtz, MS
    Slovak, ML
    Zhang, FY
    Sawyers, CL
    Forman, SJ
    Bhatia, R
    BLOOD, 2001, 98 (11) : 618A - 618A
  • [38] STI571 therapy increases the frequency of IFN-gamma-producing T cells in patients with chronic myelogenous leukemia to levels observed after allografting.
    Aswald, JM
    Lipton, JH
    Messner, HA
    BLOOD, 2001, 98 (11) : 619A - 619A
  • [39] The tyrosine kinase inhibitor STI571 restores cell cycle arrest of peripheral blood progenitor cells from patients with chronic myelogenous leukemia in vivo.
    Kraemer, A
    Loeffler, H
    Bergmann, J
    Lahaye, T
    Hochhaus, A
    Gschaidmeier, H
    Hehlmann, R
    BLOOD, 2000, 96 (11) : 344A - 344A
  • [40] Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo
    Marley, SB
    Davidson, RJ
    Lewis, JL
    Nguyen, DX
    Eades, A
    Parker, S
    Goldman, JM
    Gordon, MY
    LEUKEMIA RESEARCH, 2001, 25 (11) : 997 - 1002
12345